Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Kohlmann

Showing results (51-60 of 102) with videos related to

Pageof 11
Sort By:
Blood|July 28, 2012
Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progressionHan-Yu Chuang, Laura Rassenti, Michelle Salcedo, et al.
Plos One|February 6, 2013
Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 casesAnnette Fasan, Tamara Alpermann, Claudia Haferlach, et al.
The Journal of Molecular Diagnostics : JMD|March 1, 2011
Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technologyVera Grossmann, Susanne Schnittger, Sonja Schindela, et al.
Cytometry. Part B, Clinical Cytometry|September 2, 2003
Correlation of protein expression and gene expression in acute leukemiaWolfgang Kern, Alexander Kohlmann, Christian Wuchter, et al.
The Journal of Molecular Diagnostics : JMD|May 18, 2013
Robustness of amplicon deep sequencing underlines its utility in clinical applicationsVera Grossmann, Andreas Roller, Hans-Ulrich Klein, et al.
Haematologica|December 21, 2014
Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutationsSabine Jeromin, Torsten Haferlach, Sandra Weissmann, et al.
Blood|March 24, 2012
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entityUlrike Bacher, Susanne Schnittger, Katja Macijewski, et al.
British Journal of Haematology|January 13, 2012
EZH2 mutations and their association with PICALM-MLLT10 positive acute leukaemiaVera Grossmann, Ulrike Bacher, Alexander Kohlmann, et al.
Blood|June 29, 2010
Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC)Miriam Miesner, Claudia Haferlach, Ulrike Bacher, et al.
European Journal of Haematology|October 30, 2013
Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasmsYuewen Fu, Thomas Schroeder, Tatjana Zabelina, et al.
Pageof 11

Showing results (51-60 of 102) with videos related to

Sort By:
Pageof 11
Blood|July 28, 2012
Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progressionHan-Yu Chuang, Laura Rassenti, Michelle Salcedo, et al.
Plos One|February 6, 2013
Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 casesAnnette Fasan, Tamara Alpermann, Claudia Haferlach, et al.
The Journal of Molecular Diagnostics : JMD|March 1, 2011
Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technologyVera Grossmann, Susanne Schnittger, Sonja Schindela, et al.
Cytometry. Part B, Clinical Cytometry|September 2, 2003
Correlation of protein expression and gene expression in acute leukemiaWolfgang Kern, Alexander Kohlmann, Christian Wuchter, et al.
The Journal of Molecular Diagnostics : JMD|May 18, 2013
Robustness of amplicon deep sequencing underlines its utility in clinical applicationsVera Grossmann, Andreas Roller, Hans-Ulrich Klein, et al.
Haematologica|December 21, 2014
Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutationsSabine Jeromin, Torsten Haferlach, Sandra Weissmann, et al.
Blood|March 24, 2012
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entityUlrike Bacher, Susanne Schnittger, Katja Macijewski, et al.
British Journal of Haematology|January 13, 2012
EZH2 mutations and their association with PICALM-MLLT10 positive acute leukaemiaVera Grossmann, Ulrike Bacher, Alexander Kohlmann, et al.
Blood|June 29, 2010
Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC)Miriam Miesner, Claudia Haferlach, Ulrike Bacher, et al.
European Journal of Haematology|October 30, 2013
Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasmsYuewen Fu, Thomas Schroeder, Tatjana Zabelina, et al.
Pageof 11